Most Read Articles
06 Dec 2018
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
Pearl Toh, 22 hours ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.

TNF inhibitor improves outcomes in children with enthesitis-related arthritis

04 Jan 2018

Use of antitumour necrosis factor (anti-TNF) therapy provides benefits for several clinically meaningful outcomes in children with enthesitis-related arthritis (ERA) during the first year after diagnosis, a study has shown.

A total of 965 clinic visits the first year after disease diagnosis were reported in 217 patients with ERA during the study period. Children (median age 11.6 years; interquartile range, 10‒14) received anti-TNF monotherapy (n=33; 15.2 percent), conventional synthetic disease-modifying antirheumatic drugs (csDMARD) monotherapy (n=73; 33.6 percent), or both (n=52; 23.9 percent) in the first year after ERA diagnosis.

Over time, children administered anti-TNF drug vs those who did not had a statistically significant improvement in active joint count (p=0.03). Anti-TNF therapy exposure vs no anti-TNF therapy also correlated with less patient-reported pain (p<0.01) and improved disease activity over time based on the clinical Juvenile Arthritis Disease Activity Score (p<0.01).

Furthermore, there was consistently greater magnitude of estimated effect on clinical outcomes in children treated with an anti-TNF drug vs csDMARD, except with tender entheses count.

The investigators conducted a multicentre retrospective comparative effectiveness study to describe the effect of ant-TNF therapy vs csDMARD in children diagnosed with ERA. They used state-of-the-art comparative effectiveness analytic methods to assess the effect of anti-TNF therapy on clinical variables (active joint count and tender entheses count) and patient-reported pain and global assessment of disease activity over the first year after diagnosis.

In a study that analysed and compared the effectiveness and drug survival in patients with rheumatoid arthritis of anti-TNF monotherapy, anti-TNF plus leflunomide, anti-TNF plus sulfasalazine, anti-TNF plus other csDMARD, and anti-TNF plus methotrexate (MTX) therapy in daily practice, researchers suggested that anti-TNF therapy should be prescribed together with MTX and if not possible, with other csDMARD. [J Rheumatol 2016;43:1787-1794]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
06 Dec 2018
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
Pearl Toh, 22 hours ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.